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Biallelic UFM1 and UFC1 mutations expand the
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The post-translational modiﬁcation of proteins through the addition of UFM1, also known as ufmylation, plays a critical develop-
mental role as revealed by studies in animal models. The recent ﬁnding that biallelic mutations in UBA5 (the E1-like enzyme for
ufmylation) cause severe early-onset encephalopathy with progressive microcephaly implicates ufmylation in human brain develop-
ment. More recently, a homozygous UFM1 variant was proposed as a candidate aetiology of severe early-onset encephalopathy with
progressive microcephaly. Here, we establish a locus for severe early-onset encephalopathy with progressive microcephaly based on
two families, and map the phenotype to a novel homozygous UFM1 mutation. This mutation has a signiﬁcantly diminished capacity
to form thioester intermediates with UBA5 and with UFC1 (the E2-like enzyme for ufmylation), with resulting impaired ufmylation of
cellular proteins. Remarkably, in four additional families where eight children have severe early-onset encephalopathy with progressive
microcephaly, we identiﬁed two biallelic UFC1 mutations, which impair UFM1-UFC1 intermediate formation with resulting wide-
spread reduction of cellular ufmylation, a pattern similar to that observed with UFM1 mutation. The striking resemblance between
UFM1- and UFC1-related clinical phenotype and biochemical derangements strongly argues for an essential role for ufmylation in
human brain development. The hypomorphic nature of UFM1 and UFC1 mutations and the conspicuous depletion of biallelic null
mutations in the components of this pathway in human genome databases suggest that it is necessary for embryonic survival, which is
consistent with the embryonic lethal nature of knockout models for the orthologous genes.
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Introduction
Post-translational modiﬁcation greatly expands the func-
tional repertoire of proteins beyond the conﬁnes of their
coding sequence, and serves a diverse array of regulatory
roles in protein turnover, localization and interactions
(Hitosugi and Chen, 2014; Tompa et al., 2014).
Ubiquitination is a well-established post-translational modi-
ﬁcation involving a series of enzymatic reactions that add
ubiquitin to its target protein (Hershko and Ciechanover,
1998). These reactions involve a few E1 activating enzymes,
dozens of E2 conjugating enzymes and hundreds of E3 ligat-
ing enzymes. More than a dozen ubiquitin-like (UBL) pro-
teins have been found to similarly modify their target
proteins (Schulman and Harper, 2009). UBL are classiﬁed
into those that are activated and conjugated to substrates
(type I) e.g. SUMO, NEDD8, ATG8, ATG12, URM1,
UFM1, FAT10, and ISG15, and those that do not undergo
conjugation (type II) (Cappadocia and Lima, 2018).
UFM1 (ubiquitin-fold modiﬁer 1), a 9.1-kDa protein
with a tertiary structure similar to ubiquitin, is among the
most recently identiﬁed type I UBL proteins (Komatsu
et al., 2004). The process of covalently attaching UFM1
to its target proteins, termed ufmylation, requires E1 acti-
vating enzymes (UBA5), E2 conjugating enzymes (UFC1),
and an E3 ligase (UFL1) (Daniel and Liebau, 2014). UFM1
is activated by UBA5, forming a high-energy thioester
bond. Activated UFM1 is then transferred to UFC1, in a
similar thioester linkage (Komatsu et al., 2004). Ufmylation
is completed by the catalysis of UFM1 transfer to the sub-
strate protein through the action of the E3 enzyme UFL1
(Tatsumi et al., 2010). The physiological context of ufmy-
lation remains incompletely understood. The literature on
the relevance of ufmylation to human health was originally
limited to cancer and, to a much lesser extent, complex
diseases such as diabetes, ischaemic heart diseases and al-
coholic liver disease (Liu et al., 2014; Yoo et al., 2015; Wei
and Xu, 2016). As with other biochemical processes, how-
ever, Mendelian diseases involving deﬁciency of the individ-
ual components of ufmylation offered a unique opportunity
to reveal the extent to which ufmylation inﬂuences human
physiology. We and others have reported hypomorphic mu-
tations in UBA5 in children with severe infantile onset epi-
leptic encephalopathy (Colin et al., 2016; Duan et al.,
2016; Muona et al., 2016). Additionally, Hamilton et al.
(2017) reported that a homozygous mutation in UFM1
caused a severe early-onset encephalopathy with progres-
sive microcephaly, although the mechanism remained un-
clear. In this report, we provide evidence that it is the
process of ufmylation that is essential for normal nervous
system development and function, based on the identiﬁca-
tion of UFM1 and UFC1 biallelic mutations, which we
show lead to a remarkably similar neurological phenotype
and accompanying impairment in ufmylation.
Materials and methods
Human subjects
Patients and available relatives were recruited with informed
consent as part of IRB-approved research protocols (RAC#
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2080006 and 2121053; StV 11/09). Clinical data, including
laboratory and imaging studies, were collected from all par-
ticipants. Blood was collected in EDTA tubes for DNA extrac-
tion and in Na-heparin tubes for the establishment of
lymphoblastoid cell lines.
Autozygome analysis
Genomewide single nucleotide polymorphism (SNP) genotyp-
ing using Axiom SNP Chip (Affymetrix) from all available
patients and relatives was pursued to determine the candidate
autozygome as described before (Alkuraya, 2010, 2012).
Runs of homozygosity 42Mb were considered surrogates of
autozygosity given the consanguineous nature of the study
families as determined by AutoSNPa. Homozygosity mapping
was performed on all available family members using
HomozygosityMapper (http://www.homozygositymapper.org/).
Exome sequencing and variant
filtering
Exome capture was performed using TruSeq Exome
Enrichment kit (Illumina) following the manufacturer’s proto-
col. Samples were prepared as an Illumina sequencing library,
and in the second step, the sequencing libraries were enriched
for the desired target using the Illumina Exome Enrichment
protocol. The captured libraries were sequenced using
Illumina HiSeq 2000 Sequencer. The reads were mapped
against UCSC hg19 (http://genome.ucsc.edu/) by BWA (http://
bio-bwa.sourceforge.net/). The SNPs and indels were detected
by SAMtools (http://samtools.sourceforge.net/). Variants from
whole exome sequencing (WES) were ﬁltered such that only
novel (or very low frequency 50.1%), coding/splicing, homo-
zygous variants that are within the candidate autozygome
(autozygous intervals exclusive to the affected individuals)
and are predicted to be pathogenic were considered as likely
causal variants (Alkuraya, 2013, 2016). Frequency of variants
was determined using publicly available variant databases
(1000 Genomes, Exome Variant Server and ExAC) as well
as a database of 2369 in-house ethnically-matched exomes.
Pathogenicity is likely if the mutation is loss-of-function (spli-
cing/truncating) or, in the case of missense/in-frame indels, re-
moves a highly conserved amino acid and is predicted to be
pathogenic by the three in silico prediction modules PolyPhen,
SIFT and CADD.
In silico modelling
3D experimental structures were retrieved from the Protein
Data Bank (PDB) and analysed using PYMOL (www.pymol.
org).
Pull-down assay
Recombinant proteins were puriﬁed with glutathione S-trans-
ferase (GST) afﬁnity puriﬁcation system according to the
manufacturer’s protocol (GE Healthcare). The GST moiety of
all puriﬁed proteins without GST-UBA5 was removed on
column by PreScission protease (GE Healthcare). GST-UBA5
bound to Glutathione Sepharose 4B (GE Healthcare) was
incubated for 20min at 4C with indicated puriﬁed proteins
in pull-down assay buffer (20mM Tris-Cl, pH 7.5, 150mM
NaCl, 1mM EDTA, 1mM DTT, 0.05% Nonidet P-40). The
pulled-down protein complexes were extensively washed with
pull-down assay buffer, and the obtained samples were sub-
jected to NuPAGE (4–12% acrylamide gradient) and
Coomassie brilliant blue staining.
Cell culture
HEK293T cells were grown in Dulbecco’s modiﬁed Eagle
medium (DMEM) containing 10% foetal bovine serum
(FBS), 5U/ml penicillin, and 50 mg/ml streptomycin. Lympho-
blasts were cultured in RPMI 1640 supplemented by 10%
FBS, 5 U/ml penicillin, and 50 mg/ml streptomycin. To generate
UFM1- and UFC1-knockout cells, each UFM1 and UFC1
guide RNA designed using the CRISPR Design tool (http://
crispr.mit.edu/) was subcloned into pX330-U6-Chimeric_BB-
CBh-hSpCas9 (Addgene #42230), a human codon-optimized
SpCas9 and chimeric guide RNA expression plasmid.
HEK293T cells were co-transfected with the pX330 and
pEGFP-C1 (#6084-1, Clontech Laboratories) vectors, and cul-
tured for 2 days. Thereafter, the GFP-positive cells were sorted
and expanded. Loss of UFM1 and of UFC1 was conﬁrmed by
heteroduplex mobility assay followed by immunoblot analysis
with anti-UFM1 and anti-UFC1 antibodies, respectively.
Immunoblot analysis
Cells were lysed with ice-cold TNE buffer (10mM Tris-Cl, pH
7.5, 1% Nonidet P-40, 150mM NaCl, 1mM EDTA, and pro-
tease inhibitors). The samples were separated using the
NuPAGE system (Invitrogen) on 12% Bis-Tris gels in
NuPAGE MOPS SDS Running Buffer, and transferred to
polyvinylidene diﬂuoride (PVDF) membranes. Antibodies
against FLAG (Medical & Biological Laboratories Co., Ltd.,
M185-3L), UFC (Abcam, ab189251) and UFM1 (Abcam,
ab109305) were purchased from the indicated suppliers.
Anti–UBA5 and UFM1 polyclonal antibodies were described
previously (Komatsu et al., 2004). The immunoreactive bands
were detected by LAS-4000 (GE Healthcare UK Ltd.). The
quantitative densitometric analyses of FLAG-UBA5-MYC-
UFM1, FLAG-UFC1-MYC-UFM1, endogenous UBA5-UFM1
intermediate, and endogenous UFC1-UFM1 intermediate rela-
tive to free FLAG-UBA5, FLAG-UFC1, endogenous UBA5,
and endogenous UFC1 were carried out using Multi Gauge
Version 3.2 Image software (Fuji Film, Tokyo, Japan).
Statistical analysis was performed using an unpaired t-test
(Welch test). The data represent the means  standard error
(SE) of three separate experiments.
In vitro thioester formation assay
In vitro thioester formation assay was conducted as previously
reported (Komatsu et al., 2004). Brieﬂy, recombinant GST-
UFM1C2, GST-UFM1C2R81C, GST- UFM1Gly83, GST-
UBA5, GST-UFC1, GST-UFC1R23Q and GST-UFC1T106I were
produced in Escherichia coli and recombinant proteins were
puriﬁed by chromatography on Glutathione Sepharose 4B
(GE Healthcare). After digestion of GST by PreScission
Protease (GE Healthcare), the recombinant proteins were dia-
lyzed against 50mM BisTris (pH 6.5), 100mM NaCl, 10mM
MgCl2, and 0.1mM DTT (reaction buffer). Thioester
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formation reactions contained reaction buffer with 0.8mg
UFM1C2, UFM1C2R81C or UFM1Gly83 and some of the
following: 5mM ATP, 0.08 (for UFC1-UFM1 thioester forma-
tion assay) or 0.8 mg (for UBA5-UFM1 thioester formation
assay) UBA5 and 0.8 mg UFC1, UFC1R23Q or UFC1T106I.
Reactions were incubated for 5min at 25C and stopped by
the addition of NuPAGE LDS Sample Buffer lacking reducing
agent, followed by a 10-min incubation at 37C, NuPAGE
(4–12% acrylamide gradient) and Coomassie brilliant blue
staining. Data shown are representative of three separate
experiments.
Assessment of apoptosis in response
to endoplasmic reticulum stress
HeLa or SH-SY5Y cells were plated into six-well plates at
7.5  105 cells/ml. After 18h they were transfected with either
2mg GFP, 1mg UFM1WT/1mg GFP or 1mg UFM1R81C/1mg
GFP using FuGENE HD or X-tremeGENETM HP, respectively
according to the manufacturer’s protocols. Media was changed
after 24h and tunicamycin added after 48h. For endoplasmic
reticulum stress marker analysis, cells were incubated with 5mg/
ml tunicamycin for 8h. mRNA was extracted from cells using
the RNeasy Plus Mini Kit (Qiagen) according to the manufac-
turer’s instructions. The concentration of the mRNA was calcu-
lated and 1mg converted to cDNA using the qScriptTM cDNA
synthesis kit (Quanta Biosciences). Levels of HSPA5, DDIT3
and GAPDH were assayed using pre-designed TaqMan Gene
Expression Assays (ThermoFisher Scientiﬁc). The level of gene
expression was normalized to that of GAPDH for each sample
assessed. For assessment of apoptosis in response to endoplas-
mic reticulum stress, cells were incubated in different concentra-
tions of tunicamycin for 48h. They were then, trypsinized and
stained with Annexin V, Alexa Fluor 647 conjugate
(ThermoFisher Scientiﬁc) and DAPI to assess early and late
stages of apoptosis, respectively. Cells were analysed on a BD
LSR FortessaTM ﬂow cytometer, selecting only those expressing
GFP. Data were analysed using FlowJo software, and cells ex-
pressing either DAPI and/or Annexin V were considered
apoptotic.
Results
Identification of novel severe early
infantile encephalopathy phenotypes
Two Sudanese families were recruited independently by
C.G.W. and F.S.A., each with two children presenting
with the core phenotype of profound global developmental
delay, failure to thrive, progressive microcephaly and re-
fractive epilepsy. Salient clinical features include subtle
facial dysmorphism, severe axial hypotonia and appendicu-
lar hypertonia. Available brain imaging revealed dysmyeli-
nation and volume loss. Hypsarrhythmia was documented
on EEG. The severity of the presentation is evidenced by
the premature death of two of the four patients at ages 9
months and 8.5 years, respectively (Table 1, Fig. 1 and
Supplementary Tables 1 and 2). T
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Independently, we encountered a highly similar phenotype
in three Saudi families and one Swiss family with eight af-
fected members (one of which was previously described, albeit
brieﬂy) (Anazi et al., 2016). They all presented with severe
early infantile encephalopathy, progressive microcephaly, axial
hypotonia, appendicular hypertonia and refractory epilepsy.
Although brain MRI ﬁndings were largely non-speciﬁc,
some had evidence of basal ganglia involvement (Table 1,
Fig. 2 and Supplementary Tables 1 and 2). Phenotypic com-
parison of our patients with UFM1 and UFC1 mutations to
previously reported patients with UFM1 and UBA5 mutations
can be found in Table 2.
UFM1 and UFC1 define novel loci for
severe infantile encephalopathy with
progressive microcephaly
Although the two Sudanese families are not known to be
related, they originate from the same village in Sudan.
Indeed, autozygome analysis revealed a single shared auto-
zygous interval (Chr13:36292810-42302880) between the
affected members with the same ancestral haplotype,
strongly supporting a recessive founder mutation. Exome
sequencing of the index in each of the two families revealed
the same sole novel homozygous variant within this interval:
UFM1: NM_016617.3:c.241C4T:p.(Arg81Cys) (Fig. 1).
Similarly, genotyping of the Saudi families with a similar
encephalopathy phenotype revealed that they all share the
same ancestral haplotype (Chr1:158957700-162094700),
again supporting a recessive founder mutation (Fig. 2).
Indeed, exome sequencing on four of the seven patients
revealed a single novel homozygous variant within the crit-
ical locus: UFC1: NM_016406.3:c.317C4T:p.(Thr106Ile),
which segregated with the phenotype in all four families as
revealed by targeted Sanger sequencing. Exome sequencing
on a Swiss patient revealed a novel homozygous variant in
UFC1: NM_016406.3:c.68G4A:p.(Arg23Gln) inherited
from the heterozygous parents. Mutations at Thr106 and
Arg23 involve highly conserved residues (Fig. 2).
Hypomorphic effect of UFM1 muta-
tion on the UFM1-system
The UFM1 variant is predicted pathogenic by PolyPhen
(0.538/possibly damaging), SIFT (0/ deleterious) and CADD
(35), as are the UFC1 variants c.317C4T:p.(Thr106Ile)
Figure 1 UFM1-related clinical phenotype. (A) Pedigree of Family 1 with UFM1 mutation. (B and C) Images from Family 1 exhibiting lack of
major facial dysmorphism. (D and E) Pes cavus as a result of abnormal tone in Patients 10DG0945 and 10DG0946, respectively (Family 1). (F)
Genome-wide homozygosity mapping revealed a single critical locus. Blue box indicates haplotype (Chr13:36292810-42302880) identical by
descent. (G) Pedigree of Family 2 with UFM1 mutation. (H) Facial image of Patient UK1 (Family 2) showing full cheeks. (I and J) Peripheral oedema
of Patients UK1 and UK2 (Family 2). (K and L) Brain MRI of Patient UK1 showing cerebellar hypoplasia and thin corpus callosum and frontal
cortical polymicrogyria. (M) Schematic diagram of UFM1 protein representing ubiquitin-fold modifier 1 domain with the mutation indicated. The
Arg81 at the mutation site is highly conserved from humans to C. elegans.
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Figure 2 UFC1-related clinical phenotype. (A) Pedigrees of the families with UFC1 mutation. (B) Genome-wide homozygosity plot high-
lighting a single critical locus from Families 1–3, who harbour the p.(Thr106Ile) mutation. Blue box indicates haplotype (Chr1:158957700-
162094700) identical by descent. (C) Clinical images showing multiple joint contractures and emaciation (Patient 17DG0828). (D and E) Clinical
images of younger patients suggest a progressive nature of emaciation (Patients 14DG0050 and 16DG1614, respectively). (F) Brain MRI of Patient
16DG1614 showing bilateral hyperintense signals in the basal ganglia. (G and H) Brain MRI of Patient MDL-17-3196 showing bilateral hyperintense
signals in the basal ganglia in the first year that resolved in a repeated brain MRI in the fourth year of age. (I) Brain MRI of Patient ID76366 showing
markedly delayed myelination. (J) Schematic diagram of UFC1 protein showing UFC1 domain and mutation site. Mutations Arg23Gln and
Thr106Ile are highly conserved from humans to C. elegans.
Table 2 Comparison of phenotype between this study patients with UFM1 and UFC1mutations and those previously
reported with mutations in UFM1 and UBA5
Comparison between UFM1-UBA5-UFC1 pathway reported cases
Current cohort UFM1-related cases UBA5-related cases
Gene UFC1 UFM1 UFM1(PubMed: 28931644) UBA5
(PubMed: 27545681, 27545674, 28965491)
Mutation c.317C4T; c.68G4A c.241C4T c.-273_-271delTCA c.1111G4A
c.904C4T
c.971_972insC
c.778G4A
c.1165G4T
c.169A4G
c.503G4A
c.164G4A
c.684G 4 A
Number of cases 8 4 16 19
Failure to thrive 100% (8/8) 100% (4/4) 63% (10/16) 89% (8/9)
Short stature 88% (7/8) 100% (4/4) 75% (12/16) 77% (10/13)
Microcephaly 88% (7/8) 100% (4/4) 100% (16/16) 100% (18/18)
Global developmental delay 100% (8/8) 100% (4/4) 100% (16/16) 100% (19/19)
Seizures 50% (4/8) 100% (4/4) 75% (12/16) 84% (16/19)
Brain MRI
Basal ganglia abnormality 33% (2/6) 0% (0/4) 100% (16/16) 0% (0/17)
Delayed CNS myelination 17% (1/6) 75% (3/4) 100% (16/16) 24% (4/17)
Cerebellar hypoplasia 0% (0/6) 75% (3/4) 81% (13/16) 24% (4/17)
Mortality 0% (0/8) 100% (4/4) 56% (9/16) 24% (4/19)
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Figure 3 Hypomorphic effect of the UFM1 mutation on the UFM system. (A) Molecular basis for the effect of the UFM1R81C
mutation. Top: Crystal structure of the heterodimeric complex between UFM1 (magenta and yellow) and UBA5 (cyan and green), taken from PDB
id 5IAA. Bottom: Magnification of the boxed region. The view is tilted horizontally by 30 compared to the top panel. For clarity, only side chains
of Arg81 and of Arg81-interacting residues are shown. (B) In vitro pull-down assay. Pull-down assay with GST-UBA5 and UFM1, UFM1 mutants or
LC3B. GST-UBA5 conjugated with Glutathione Sepharose 4B was incubated with purified recombinant UFM1, UFM1 mutants or LC3B. LC3B is
known to interact with UBA5. The pulled-down complexes were subjected to NuPAGE (4–12% acrylamide gradient) and Coomassie brilliant
blue staining. GST-UBA5, LC3B, UFM1 and UFM1 mutants are indicated. (C and D) Immunoblot assay. Indicated constructs (0.1 mg for UBA5C250S,
0.5 mg for UFC1C116S, and 2mg for UFM1 or mutants) were expressed in UFM1-deficient HEK293T cells. Twenty-four hours after transfection, the
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[PolyPhen (0.998/probably damaging), SIFT (0/deleterious),
CADD (32)] and c.68G4A:p.(Arg23Gln) [PolyPhen (0.901/
probably damaging), SIFT (0.02/deleterious) and CADD (35)].
We therefore carried out experiments to assess if and in which
way these mutations affect ufmylation. The C-terminal tail of
UFM1 (residues 79–83) is essential for its adenylation by the
E1 enzyme UBA5 and subsequent thioester formation with
UBA5 (Oweis et al., 2016). The crystallographic structure of
UBA5 in the complex with UFM1 (PDB ID 5IAA) shows that
the tail region, encompassing Arg81, directly binds to UBA5
(Fig. 3A). Since Arg81 interacts with the negatively charged
residues Glu241, Glu209 and Asp183 of UBA5 (Fig. 3A). The
substitution of Arg81 with a shorter and hydrophobic Cys is
expected to markedly reduce the strength of the interaction
between UFM1 and UBA5. Accordingly, an in vitro pull-
down assay revealed that the mutant has a lower binding
afﬁnity to UBA5 than wild-type UFM1 (Fig. 3B). Next, we
investigated whether UBA5 is able to activate UFM1R81C. To
do this, we used a UBA5-mutant whose active site, cysteine
(Cys250) was substituted with a serine (termed UBA5C250S).
When the cysteine residue at the active site of E1 and E2
enzymes is replaced by a serine, an O-ester bond instead of
a thioester bond is formed with its respective modiﬁer pro-
teins, which become stable even under reducing conditions
(Komatsu et al., 2004). To exclude an effect of endogenous
UFM1, we generated UFM1-deﬁcient HEK293T cells
(Supplementary Fig. 1A). As expected, when we co-expressed
FLAG-UBA5C250S and wild-type MYC-UFM1 into UFM1-de-
ﬁcient HEK293T cells, MYC-UFM1 formed a stable inter-
mediate with FLAG-UBA5C250S (Fig. 3C). Such intermediate
formation was completely abrogated when UBA5C250S was
co-expressed with MYC-UFM1Gly83, whose Gly83 essential
for the adenylation and activation through UBA5 is deleted
(Fig. 3C). Though we still observed the intermediate in the
case of MYC-UFM1R81C, its level was only 75% of that of
wild-type UFM1 (Fig. 3C).
The defective activation of UFM1R81C by the UBA5 E1
enzyme is expected to also hamper the subsequent step,
namely the formation of the intermediate with its cognate
E2-like enzyme UFC1. Therefore, we investigated whether
UFM1R81C forms an intermediate with UFC1 in cells.
When wild-type MYC-UFM1 was expressed together with
FLAG-UFC1C116S in which the active site, cysteine (Cys116),
was substituted with serine, we clearly detected the
intermediate of UFC1C116S with MYC-UFM1 (Fig. 3D).
Conversely, the formation of the UFM1-UFC1 intermediate
was almost abolished when MYC-UFM1R81C or MYC-
UFM1Gly83 were expressed together with UFC1C116S
(Fig. 3D). In good agreement with those analyses, an
in vitro thioester formation assay revealed that while
wild-type UFM1 forms an intermediate with UBA5,
UFM1R81C slightly had the ability to form the intermediate
(Fig. 3E). We also observed that UFM1R81C is hardly trans-
ferred to UFC1 (Fig. 3F). In the next series of experiments,
we tested the effect of the UFM1R81C mutation on the
intermediate formation with endogenous UBA5 and UFC1
as well as UFM1-conjugation, using lymphoblasts derived
from an affected individual. Expression of free UFM1 pro-
tein in lymphoblasts from an affected individual was com-
parable to control cells (Fig. 3G, left panel). By
immunoblot analysis with non-reducing samples, we de-
tected the intermediates of UFM1-UBA5 and of UFM1-
UFC1. As predicted, the level of UFM1-UBA5 intermedi-
ates was signiﬁcantly lower in lymphoblasts of affected in-
dividual compared to control cells (Fig. 3G, middle panel).
Likewise, the formation of the UFM1-UFC1 intermediate
markedly declined (Fig. 3G, right panel). We also found
that the level of two UFM1-conjugates with cellular pro-
teins in patient-derived lymphoblasts was signiﬁcantly
reduced compared to control lymphoblasts (Fig. 3G, left
panel). Taken together, our data show that UFM1R81C
has a hypomorphic effect on the UFM1-system and provide
a plausible mechanistic explanation.
Hypomorphic effect of UFC1 muta-
tions on the UFM1-system
The UFC1 structure consists of the catalytic core domain
conserved in all E2-like enzymes and an additional N-ter-
minal helix (Mizushima et al., 2007). Thr106 on the UFC1
structure is on the opposite site of the proposed UBA5
binding site (involving helix 2) (Liu et al., 2009), suggest-
ing that mutation of this residue does not affect the inter-
action with UBA5. Indeed, an in vitro pull-down assay
showed that the Thr106Ile mutation does not have any
effect on binding to UBA5 (Supplementary Fig. 2). Thr106
is located in a coiled region close to the catalytic Cys116,
Figure 3 Continued
cell lysates were subjected to immunoblot analysis with anti-FLAG antibody. Bar graphs indicate the quantitative densitometric analyses of FLAG-
UBA5-MYC-UFM1 and FLAG-UFC1-MYC-UFM1 intermediates relative to free FLAG-UBA5 and FLAG-UFC1, respectively. Statistical analyses
were performed using the unpaired t-test (Welch test). The data represent the means  SE of three separate experiments. **P5 0.01 and
***P5 0.001. (E and F) In vitro thioester formation assay of UFM1 by UBA5 (E) and of UFM1 by UFC1 (F). The assay was conducted as described
in the ‘Materials and methods’ section. Data shown are representative of three separate experiments. (G) Immunoblot analysis in case (P1:
10DG0945, Individual V1 in Fig. 1A) and control (C1: a healthy Sudanese young female) lymphoblasts. Reducing (DTT plus) and non-reducing
(DTT minus) samples were prepared from lymphoblasts and subjected to immunoblot analysis for UFM1 (left), UBA5 (middle), and UFC1 (right).
We used a hand-made anti-UFM1 antibody in this experiment since the commercial antibody did not recognize UFM1R81C. Bar graphs indicate the
quantitative densitometric analyses of UBA5-UFM1 and UFC1-UFM1 intermediates relative to free UBA5 and UFC1, respectively. Statistical
analysis was performed using the unpaired t-test (Welch test). The data represent the means  SE of three separate experiments. **P5 0.01 and
***P5 0.001.
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Figure 4 Hypomorphic effect of UFC1 mutants on the UFM system. (A) Localization of the key binding sites on UFC1. Binding sites for
E1 and E3 are indicated. Boxed region shows the active site, and the coiled region for binding site to UFM1 is coloured in orange. The mutated
residues Arg23 and Thr106 are highlighted in yellow and green, respectively. Encircled region shows the proximity of R23 with regions involved in
binding to E1 (helix 2) and E3 (Tyr90, Pro91, Pro130; cyan). (B) Bottom: Magnification of Thr106. Residues involved in hydrophobic or polar
interactions with Thr106 are shown as stick models. Colouring as in A, except for the mutant Ile106, which is shown as light grey stick model, with
positions of minor clashes indicated as discs. Top: Magnification of Arg23. Colouring as in A, except for the mutant Gln23, which is shown as
magenta stick model. (C) Immunoblot assay. Indicated constructs (0.5 mg for UFC1C116S, UFC1C116S/T106I or UFC1C116S/R23Q and 2mg for UFM1)
were expressed in UFC1-deficient HEK293T cells. Twenty-four hours after transfection, the cell lysates were subjected to immunoblot analysis
with indicated antibodies. Bar graphs indicate the quantitative densitometric analyses of FLAG-UFC1-MYC-UFM1 intermediates relative to free
FLAG-UFC1. Statistical analyses were performed using the unpaired t-test (Welch test). The data represent the means  SE of three separate
experiments. *P5 0.05. (D) In vitro thioester formation assay of UFM1 by UFC1. The assay was conducted as described in the ‘Materials and
methods’ section. Data shown are representative of three separate experiments. (E) Immunoblot analysis in case (P2, P3, P4: V:1) and control
(C1: a healthy Sudanese young females) lymphoblasts. Reducing (DTT plus) and non-reducing (DTT minus) samples were prepared from
lymphoblasts and subjected to immunoblot analysis for UFC1 (left), and UFM1 (right). Bar graph indicates the quantitative densitometric analysis of
UFC1-UFM1 intermediates relative to free UFC1. Statistical analysis was performed using the unpaired t-test (Welch test). The data represent the
means  SE of three separate experiments. **P5 0.01.
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and within the site mapped to be required for interactions
with UFM1 (Liu et al., 2009) (orange segment in Fig. 4A).
In the crystal structure of unliganded UFC1, Thr106 inter-
acts with the hydrophobic core of the protein and is mostly
excluded from the solvent (Fig. 4B). Replacing the polar
threonine with the slightly larger and completely hydropho-
bic isoleucine is expected to change the anchoring, stereo-
chemistry and dynamics of this region, affecting the
intermediate formation of UFM1 with UFC1. Similarly,
Arg23 is close (10 A˚) to the residues Tyr90, Pro91 and
Pro130 that form a substructure and is potentially involved
in E3-binding (Liu et al., 2009) (Fig. 4A). Arg23 is also near
to the helix 2, which is involved in binding to E1
(Mizushima et al., 2007). Consequently, the substitution
of the positively charged Arg23 with a shorter and un-
charged glutamine may affect binding of UFC1 to E1 or
E3 (Fig. 4B). Therefore, we tested whether the UFC1T106I
and UFC1R23Q variants impact on the ufmylation. To do
this, HEK293T cells deleting UFC1 were generated
(Supplementary Fig. 1B), and MYC-UFM1 together with
FLAG-UFC1C116S, FLAG-UFC1T106I/C116S or FLAG-
UFC1R23Q/C116S was expressed in the UFC1-deﬁcient
HEK293T cells. While an UFC1-UFM1 intermediate was
clearly detected in FLAG-UFC1C116S-expressing UFC1-deﬁ-
cient HEK293T cells, only a faint intermediate formation
was observed in the case of FLAG-UFC1T106I/C116S and
FLAG-UFC1R23Q/C116S (Fig. 4C). Our in vitro thioester for-
mation assay also showed that while wild-type UFC1
formed an intermediate with UFM1, UFC1T106I and
UFC1R23Q substantially reduced this ability (Fig. 4D). In
lymphoblasts isolated from three affected individuals with
UFC1T106I, the intermediate formation with endogenous
UFM1 was signiﬁcantly suppressed in comparison with
that in control lymphoblasts (Fig. 4E, left panel). Similar
to the case of UFM1R81C, the UFM1-conjugate formation
with cellular proteins was impaired in patient-derived
lymphoblasts (Fig. 4E, right panel). Taken together, we
concluded that although the mutations UFM1R81C and
UFC1T106I UFC1R23Q affect different proteins, they all
impact ufmylation. Hence our analysis explains the similar
patient phenotype by showing that these mutations cause
phenotypically similar hypomorphic effects on the UFM1-
system.
Mutation in UFM1 does not affect
endoplasmic reticulum stress-
mediated apoptosis
Studies have reported that the pathogenesis of ufmylation-
related encephalopathy is associated with endoplasmic re-
ticulum stress-mediated apoptosis. Thus we tested UFM1
mutation (p.R81C) effect on endoplasmic reticulum stress.
We found no signiﬁcant impact of UFM1 wild-type or
mutant expression on the induction of endoplasmic reticu-
lum stress markers CHOP (DDIT3) and BIP (HSPA5) in
either HeLa or SH-SY5Y cells, after 8 h treatment with
5 mg/ml tunicamycin (Supplementary Fig. 3). Neither did
we note appreciable difference in endoplasmic reticulum
stress-induced apoptosis in cells expressing UFM1 wild-
type or UFM1 p.R81C, after 48 h incubation in tunicamy-
cin at various concentrations.
Discussion
Our understanding of the pathogenesis of infantile encephal-
opathy at the molecular level has greatly expanded in recent
years due in large part to the rapidly growing use of gen-
omics to diagnose and classify this highly heterogeneous
group of disorders. The remarkable diversity and breadth
of implicated molecular pathways are consistent with the
highly complex nature of the brain (Hamdan et al., 2017).
Indeed, the observation that the majority of these conditions
are not associated with signiﬁcant systemic ﬁndings, further
supports the notion that brain vulnerability is inherent to its
complexity. This is especially remarkable when one considers
the fundamental and ubiquitous nature of the many biolo-
gical processes that are impaired in the various genetic forms
of infantile encephalopathy, including post-translational mod-
iﬁcation (Alazami et al., 2015; Anazi et al., 2016, 2017).
Ufmylation is a highly conserved post-translational mod-
iﬁcation with each of its components having a corresponding
orthologue in all multicellular organisms. In this study, we
show that this pathway is critically required for normal
brain development and function in humans consistent with
suggestive data from model organisms. For example, the
fruitﬂy models of UBA5 and UFM1 deﬁciency display
increased mortality, locomotive defects, and abnormal
neuromuscular junctions (Duan et al., 2016). Similarly, deﬁ-
ciency of the UBA5 orthologue in Caenorhabditis elegans
results in increased susceptibility to induced seizures and
pharynx grinder paralysis as well as abnormal sensorial be-
haviour (Colin et al., 2016). Impaired motility and seizure-
like activity were also observed in zebraﬁsh uba5 morphants
(Colin et al., 2016). More relevant to the phenotype of the
patients we described in this study is our recently published
brain-speciﬁc conditional knockout of Ufm1 under the
nestin promoter (Muona et al., 2016), which allowed us to
directly observe the brain pathology associated with im-
paired ufmylation in vivo. Although these mice appeared
normal at birth, they uniformly died in the ﬁrst day after
birth. Histopathological examination revealed that their
brains were microcephalic with evidence of increased apop-
tosis, consistent with the proposed role of ufmylation in
neuronal development and survival (Muona et al., 2016).
Similar to our previous work on UBA5-related severe
infantile encephalopathy, we show that mutations in
UFM1 itself as well as in UFC1, encoding the sole E2
conjugating enzyme for UFM lead to widespread impair-
ment of ufmylation. Our results show a reduction rather
than abrogation of ufmylation with the activity of UFM1
and UFC1 mutants at 60–75% of their wild-type counter-
parts. A recently reported promoter mutation in UFM1 in
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the context of infantile encephalopathy with or without
epilepsy is similarly predicted to only reduce but not elim-
inate transcription of an otherwise normal transcript
(Hamilton et al., 2017). The clinical phenotype of previ-
ously reported patients with UBA5 (Colin et al., 2016;
Duan et al., 2016; Muona et al., 2016) and UFM1
(Hamilton et al., 2017) mutations are similar to our
UFM1 and UFC1 patients, particularly regarding failure
to thrive, short stature, microcephaly, GDD, seizures,
basal ganglia abnormality, delayed CNS myelination, and
cerebellar hypoplasia (Table 2). These observations strongly
argue for a minimum threshold required for embryonic via-
bility, and this would be consistent with the mouse embry-
onic lethal phenotype observed in the complete knockout of
Uba5, Ufbp1, Uﬂ1 or Ufm1 (M.K., unpublished data)
(Tatsumi et al., 2011; Cai et al., 2015; Zhang et al., 2015).
The pathogenesis of ufmylation-related encephalopathy
remains unclear e.g. is the disease process a progressive
apoptosis of selected neuron classes, or a neuronal dysfunc-
tion that becomes increasingly evident during development?
The known localization of the ufmylation cascade and
target proteins to the luminal side of the endoplasmic re-
ticulum and the proposed role in regulating the unfolded
protein response (UPR) and endoplasmic reticulum stress-
mediated apoptosis, suggest a potential mechanistic link
(Lemaire et al., 2011; Zhang et al., 2015; Ishimura et al.,
2017). Expanded endoplasmic reticulum network and
increased endoplasmic reticulum volume in response to
tunicamycin, both markers of endoplasmic reticulum
stress, have indeed been observed in ﬁbroblasts from pa-
tients with UBA5 mutations (Colin et al., 2016). Long-term
endoplasmic reticulum stress driven by mutation of speciﬁc
disease-related genes is known to cause various adult-onset
neurodegenerative phenotypes by overwhelming the UPR
and inducing apoptosis (Hetz and Saxena, 2017). While
we found no evidence of UFM1 wild-type or p.R81C over-
expression affecting endoplasmic reticulum stress induction
or apoptosis in response to tunicamycin (Supplementary
Fig. 3), further work should serve to investigate the mech-
anisms by which defects in ufmylation lead to early-onset
encephalopathy in humans. However, it may be that the
ufmylation cascade, rather than a global effect on endoplas-
mic reticulum or UPR, could disrupt neuron function
through effects on neural-essential proteins; the neuronal
cell adhesion molecule (NCAM) interacts and co-localizes
with UFC1, and CDK5 activity is controlled by
CDK5RAP3, which aggregates with UFL1 and UFSP2 at
the endoplasmic reticulum membrane (Homrich et al.,
2014).
In conclusion, our study suggests that impaired ufmyla-
tion leads to a recognizable syndrome of severe infantile
encephalopathy and progressive microcephaly with or with-
out epilepsy. Further studies are needed to discern the exact
pathomechanism of ufmylation-related neurodevelopmental
disorder, which may lead to possible therapies especially
when one considers the hypomorphic nature of the
observed mutations.
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